Alle Storys
Keine Story von Biocartis mehr verpassen.


Biocartis Strengthens Management Team With Chief Commercial Officer

Belgium (ots/PRNewswire)

Biocartis, a molecular diagnostics company, announces today that Ulrik Cordes has joined the company as Chief Commercial Officer (CCO). Ulrik Cordes is an executive with 18+ years of experience in marketing and sales in the med-tech, pharma and biotech industry, of which the past 10 years in top level management roles.

"We are delightedtowelcomeUlrik to Biocartis' ExecutiveTeam,"saidRudi Pauwels, CEO and Chairman of Biocartis. "We are transforming from a development company into a commercial business. The addition of Ulrik will be key to achieving our ultimate goal to making personalized medicine a day-to- day reality by building a global business. Ulrik possesses a unique combination of experience and success in building winning commercial strategies and attracting world class sales and sales support professionals."

Ulrik Cordes joins Biocartis most recently from Thermo Fisher Scientific, where he held the position of Global Sales & Marketing Director Slides & Specialty Glass since March 2012. Since 2002 Ulrik worked at DAKO A/S - A World-leading Company in Cancer Diagnostics, where he held a number of positions with increasing responsibility, most recently as Vice President Marketing Operations and Vice President Asia Pacific & Export Region.

He started his career in 1995 in Pharmacia Biotech A/S (now part of GE Healthcare). Ulrik received his Master of Science in Biochemistry from the University of Copenhagen and holds a Bachelor of Commerce (HD) from Copenhagen Business School.

About Biocartis ( Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis' ambition is to establish a new gold standard in diagnostic testing. Biocartis' innovative research and diagnostic systems are characterized by multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients.

Biocartis is a rapidly growing company; to date Biocartis staff includes over 170 people.


Contact Rudi Pauwels, CEO, Tel: +32-15-632-600 (Mechelen) , Tel:
+41-21-694-04-30 (Lausanne) ,

Weitere Storys: Biocartis
Weitere Storys: Biocartis
  • 15.01.2013 – 15:32

    Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology

    Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...

  • 12.12.2012 – 14:07

    Biocartis Completes ?34,5 Million ($44,5 Million) Series D Fund Raising

    Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...

  • 05.12.2012 – 14:04

    Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

    Lausanne, Switzerland (ots/PRNewswire) - Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"): - New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats. - Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial ...